RxDoctor Payments DataLook up a doctor →

Bassam Awwa, MD

Psychiatry · New London, CTNPI 1881774354

Payments from drug & device makers

$92,630in general payments, 2019–2025

Across 1,143 payments — averaging $81.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$72K
  • Johnson & Johnson$2K
  • Supernus Pharmaceuticals, Inc.$2K
  • Sunovion Pharmaceuticals Inc.$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Ironshore Pharmaceuticals Inc.$2K
  • plus $11K from 29 others

What the payments were for

  • Speaking & faculty fees$66,28572%
  • Travel & lodging$2,7493%
  • Food & beverage$23,38125%
  • Education$2150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$92,630 in reported general payments places this provider in the 95th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$155,021
Medicare patients
139
Services billed
1,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl399$480,446
VraylarCariprazine Hcl160$253,252
SuboxoneBuprenorphine Hcl/Naloxone Hcl113$59,948
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl336$35,738
TrintellixVortioxetine Hydrobromide41$31,517
Lurasidone Hcl35$23,337
Aripiprazole208$17,646
RexultiBrexpiprazole11$12,280
VyvanseLisdexamfetamine Dimesylate31$11,935
TopamaxTopiramate14$8,184
Desvenlafaxine Succinate ErDesvenlafaxine Succinate69$7,357
Clonazepam737$7,225
Paroxetine Hcl37$7,026
ConcertaMethylphenidate Hcl14$6,153
Quetiapine Fumarate343$6,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato, Concerta$2,170$486,600413 claims
AbbVieVraylar$72,491$253,252160 claims
Indivior Inc.Suboxone$91$59,948113 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$1,582$43,45172 claims
Otsuka America Pharmaceutical, Inc.Rexulti$964$12,28011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in New London

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →